论文部分内容阅读
为了从临床观察血卟啉衍生物（ＨＰＤ）对鼻咽癌是否有加强放疗效应的作用，作者选取病理确诊１～Ⅳａ期初诊鼻咽癌９８例，按Ｔ、Ｎ、Ｍ和性别配对分为ＨＰＤ加放射组（实验组）和单纯放射组（对照组），均采用５０钴γ射线连续常规分割放射治疗。从鼻咽间接镜检查和ＣＴ扫描检查分析鼻咽原发灶的消退情况来看，实验组全消率分别为１００％，６５．３％，对照组全消率分别为７３．５％，３２．７％，两组差别有统计学意义（Ｐ＜０．０１）；颈部淋巴结转移灶，实验组全消率为９２．３％，明显高于对照组５９％（Ｐ＜０．０１）；计算ＨＰＤ的放射增敏比为１．４－１．５；两组急性放射反应和毒性反应无差别，说明血卟啉衍生物能提高鼻咽癌放疗的近期效应，配合放疗是安全的，远期疗效则有待观察。
In order to observe the effect of hematoporphyrin derivative (HPD) on nasopharyngeal carcinoma (NPC) from clinical observation, 98 cases of nasopharyngeal carcinoma were newly diagnosed by pathology in stage 1 ~ Ⅳa. T, N, M and sex matched HPD plus radiotherapy group (experimental group) and radiotherapy alone group (control group), using 50 cobalt gamma ray continuous conventional radiotherapy. From the nasopharyngeal indirect microscopy and CT scan analysis of the regression of the primary nasopharyngeal situation, the experimental group, the complete elimination rate were 100%, 65.3%, the control group, the total elimination rates were 73.5%, 32 .7%, the difference between the two groups was statistically significant (P <0.01); neck lymph node metastases, the experimental group of the total elimination rate was 92.3%, significantly higher than the control group 59% (P <0.01) ; Calculated HPD radiosensitization ratio of 1.4-1.5; two groups of acute radiation reaction and toxicity was no difference, indicating hematoporphyrin derivatives can enhance the immediate effect of radiotherapy of nasopharyngeal carcinoma, with radiotherapy is safe, Long-term efficacy remains to be seen.